Physician
Scolin, Tatiana
Scolin, Tatiana was paid $2.26M by Medicaid between Jan 2018 and Dec 2024, across 63 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 40% of everything it billed.
33Billing provider infoSCOLIN, TATIANA
WHEELING, IL 60090
WHEELING, IL 60090
33aNPI1265447676assigned 07/31/2006
33bProvider typePediatrics Physician
28Total paid$2.26M
24GClaims82,190
24DCodes billed63
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Illinois
Rank by total paid#37 of 1,805
Median peer was paid$55K
This provider vs. median41×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,154 | $286K | |
| 2019 | 11,743 | $330K | |
| 2020 | 11,020 | $258K | |
| 2021 | 11,475 | $348K | |
| 2022 | 13,064 | $362K | |
| 2023 | 13,114 | $325K | |
| 2024incomplete | 12,620 | $354K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 40% | 18,431 | 14,514 | $909K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 9.5% | 632 | 542 | $216K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 6.2% | 1,881 | 1,621 | $141K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 6.0% | 1,786 | 1,533 | $136K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 5.7% | 8,170 | 7,372 | $128K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 5.3% | 1,444 | 1,193 | $119K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.8% | 1,248 | 1,094 | $86K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.7% | 1,713 | 1,519 | $61K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.5% | 1,803 | 1,651 | $57K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.9% | 171 | 158 | $43K |
| 92551 | 1.8% | 2,654 | 2,357 | $40K | |
| 87081 | 1.5% | 6,002 | 5,355 | $35K |
51 more codes
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.2% | 1,661 | $27K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 1,460 | $24K |
| 96127 | 1.0% | 1,558 | $23K | |
| 99173 | <1% | 2,258 | $17K | |
| 83655 | <1% | 1,372 | $16K | |
| 80053 | Comprehensive metabolic panel | <1% | 1,526 | $16K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,746 | $16K |
| 84439 | <1% | 1,723 | $15K | |
| 90670 | <1% | 744 | $15K | |
| 80061 | Lipid panel | <1% | 1,515 | $11K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 616 | $11K |
| 81003 | <1% | 5,056 | $11K | |
| 80050 | General health panel | <1% | 205 | $10K |
| 85018 | <1% | 4,128 | $10K | |
| 36416 | <1% | 2,274 | $9K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,573 | $9K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 707 | $8K |
| 99000 | <1% | 315 | $7K | |
| 90677 | <1% | 136 | $6K | |
| 90734 | <1% | 225 | $5K | |
| 90686 | <1% | 402 | $4K | |
| 90700 | <1% | 282 | $3K | |
| 90619 | <1% | 191 | $3K | |
| 90710 | <1% | 57 | $2K | |
| 90648 | <1% | 171 | $2K | |
| 90715 | <1% | 124 | $2K | |
| 90744 | <1% | 120 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 191 | $1K |
| 84481 | <1% | 100 | $1K | |
| 90633 | <1% | 86 | $957.43 | |
| 87428 | <1% | 15 | $953.85 | |
| 90696 | <1% | 46 | $883.57 | |
| 90716 | <1% | 43 | $794.64 | |
| 90698 | <1% | 48 | $533.89 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 15 | $384.75 |
| 86580 | <1% | 95 | $380.00 | |
| 90621 | <1% | 17 | $376.54 | |
| 86800 | <1% | 29 | $342.20 | |
| 90651 | <1% | 30 | $315.72 | |
| 83525 | <1% | 31 | $274.66 | |
| 86376 | <1% | 27 | $230.43 | |
| 90707 | <1% | 26 | $228.64 | |
| 90713 | <1% | 13 | $180.67 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 17 | $166.77 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12 | $126.00 |
| 99051 | <1% | 33 | $90.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 17 | $19.04 |
| 1003F | 0% | 680 | $0.00 | |
| 99072 | 0% | 91 | $0.00 | |
| 1040F | 0% | 216 | $0.00 | |
| 1036F | 0% | 232 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.